B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains ...

Maxim lowered the firm’s price target on Viking Therapeutics (VKTX) to $70 from $120 and keeps a Buy rating on the shares after the company’s ...

Stock investors may look back at 2025 as the year of the takeover - one that delivered sizeable gains. "It's going to be a big year," Calamos Investments senior portfolio manager Brandon Nelson ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

Fate’s Market in Remus Michigan partners with Great Start Collaborative of Mecosta, Osceola counties to make shopping into a learning experience for children.

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...